Priti Hegde is a director of Tcr2 Therapeutics Inc.
Person profile
Roles
Address
Cambridge, Massachusetts
Employees
SEC CIK
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Adaptimmune Therapeutics PLC
1 Jul 24
4
Adaptimmune Therapeutics PLC
5 Jul 23
4
Adaptimmune Therapeutics PLC
3 Jul 23
3
Adaptimmune Therapeutics PLC
1 Jun 23
4
TCR2 THERAPEUTICS INC.
1 Jun 23
4
TCR2 THERAPEUTICS INC.
19 Dec 22
4
TCR2 THERAPEUTICS INC.
10 Dec 21
4
TCR2 THERAPEUTICS INC.
26 Aug 21
3
TCR2 THERAPEUTICS INC.
26 Aug 21
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jul 24 | ADAP Adaptimmune Therapeutics | Option to purchase Ordinary Shares Ordinary Shares | Grant | Acquire A | No | No | 0.16 | 1,144,686 | 183.15 k | 1,144,686 |
3 Jul 23 | ADAP Adaptimmune Therapeutics | Option to purchase Ordinary Shares Ordinary Shares | Grant | Acquire A | No | No | 0.16 | 500,000 | 80.00 k | 500,000 |
1 Jun 23 | TCRR Tcr2 Therapeutics | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16.02 | 24,968 | 399.99 k | 0 |
1 Jun 23 | TCRR Tcr2 Therapeutics | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.21 | 12,100 | 63.04 k | 0 |
1 Jun 23 | TCRR Tcr2 Therapeutics | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.97 | 16,800 | 16.30 k | 0 |